Pixium Vision announces final share capital breakdown and strengthening of two historical investors following successful completion of capital increase over €7.3 million

Pixium Vision announces final share capital breakdown and strengthening of two historical investors following successful completion of capital increase over €7.3 million

Paris, 15 July 2020 – 7.00 a.m. CET – Pixium Vision (Euronext Growth Paris - FR0011950641 - ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, today announces the final breakdown of the share capital following the successful completion of the capital increase.

The successful capital increase allowed Pixium Vision to raise €7.3million by issuing 14,684,919 new shares at €0.50 per share. Historical investors such as Sofinnova and Bpifrance increased their holding in Pixium Vision while Omnes Capital Concert and Abingworth did not participate in this round. Omnes Capital Concert holding in the firm has decreased below the 5% holding threshold, this passive crossing threshold resulting from the increase of the number of shares made up the share capital.

“I would like to thank all our shareholders, particularly Sofinnova and Bpifrance Participations for renewing their trust in Pixium Vision’s ambitious project. The Prima System is progressing well towards a European and US launch and we are excited for the possibility of submitting the PRIMAvera pivotal study in the very near term, with the start expected later this year or in the first half 2021. Our transition from a Research to a commercial organization is well underway alongside an increased presence in the US. We look forward to upcoming opportunities to showcase the Prima system and the Pixium Vision equity story to US investors” said Lloyd Diamond, Chief Executive Officer of Pixium Vision.

The breakdown of the share capital of the Company after the Capital Increase is the following:

	After Capital Increase
	Number of shares and voting rights	% of share capital and voting rights
Sofinnova Capital VII	6,637,048	15.89%
Innobio	2,134,094	5.11%
Bpifrance Participations	4,016,250	9.62%
Groupe Bpifrance[*]	6,150,344	14.73%
Abingworth Holdings Sàrl	2,086,720	5.00%
Omnes Capital concert	1,436,794	3.44%
Bernard Gilly	159,236	0.38%
Treasury shares	79,147(1)	0.19%
Free float	25,211,032	60.37%
TOTAL	41,760,321	100.00%

 (1) Non-voting treasury shares held by the Company at 30 June 2020.